1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated Dec 2011. www.goldcopd.org/.
2. O’Donnell DE, Parker CM. COPD exacerbations: Pathophysiology. Thorax 2006; 61; 354–61.
3. Parker CM, Voduc N, Aaron SD et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420–8.
4. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
5. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 151: 1418–22.
6. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006; 5: 343–9.
7. Miravitlles M, Murio C, Guerrero T et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–55.
8. Celli BR, Barnes PJ. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–38.
9. Smeeth L, Thomas SL, Hall AJ et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611–18.
10. Seneff MG, Wagner DP, Wagner RP et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–7.
11. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–7.
12. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Antiinfect Ther 2006; 4: 101–24.
13. Dever LL, Shashikumar K, Johanson WG. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Exp Opin Invest Drugs 2002; 11: 911–25.
14. Siempos II, Dimopoulos G, Korbila IP et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37.
15. Woodhead M, Blasi F, Ewig S et al.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
16. O’Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J 2008; 15 (Suppl. A): 1A–8A.
17. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
18. Spencer S, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–93.
19. Hurst JR, Donaldson GC, Quint JK et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369–74.
20. Wilson R, Anzueto A, Miravitlles M et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J COPD 2011; 6: 373–83.
21. Wilson R, Anzueto A, Miravitlles M et al. Moxifloxacin vs amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results. ERJ Express. Published on December 1, 2011 as doi: 10.1183/09031936.00090311.
22. Aaron SD, Fergusson D, Marks GB et al.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122–8.
23. Nalepa P, Dobryniewska M, Busman T, Notario G. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 2003; 19: 411–20.
24. Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007; 55: 226–32.
25. Miravitlles M, Espinosa C, Fernandez-Laso E et al.; and Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40–6.
26. Albertson TE, Louie S, Chan AL. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J Am Geriatr Soc 2010; 58: 570–9.
27. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345–52.
28. Petitpretz P, Chone C, Tremolieres F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007; 30: 52–9.
29. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 191–204.
30. Alvarez-Sala JL, Kardos P, Martinez-Beltran J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762–7.
31. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.
32. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
33. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355–65.
34. Aaron SD, Vandemheen KL, Hebert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618–25.
35. Daniels JM, Snijders D, de Graaff CS et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150–7.
36. Roede BM, Bresser P, Bindels PJ et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008; 63: 968–73.
37. Niewoehner DE. Clinical Practice. Outpatient management of severe COPD. N Engl J Med 2010; 362: 1407–16.
38. Calverley P, Pauwels R, Vestbo J Jones et al.; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–56.
39. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2011; 52 (Suppl. 4): S290–S295.
40. Wilson R, Jones P, Schaberg T et al.; and for the Mosaic Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–42.
41. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
42. Qaseem A, Snow V, Shekelle P et al.; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147: 633–8.
43. Dimopoulos G, Siempos II, Korbila JP et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest 2007; 132: 447–55.

С.Н.Авдеев 

ФГУ Научно-исследовательский институт пульмонологии ФМБА России, Москва